Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 15 de 15
Filter
Add more filters










Publication year range
1.
Neurourol Urodyn ; 40(8): 1889-1899, 2021 11.
Article in English | MEDLINE | ID: mdl-34453858

ABSTRACT

AIMS: Detrusor underactivity (DU) is an understudied health concern with inadequate clinical management. The pathophysiology of DU is unclear, and current therapies fail to improve symptoms. The current studies characterized voiding function and contractility of bladder and urethral tissues in a novel rat model of DU. METHODS: Female obese prone (OP) and obese resistant (OR) rats were fed a 60 kcal% fat diet at 8 weeks old. A subset of rats (n = 4/strain) underwent uroflowmetry biweekly for 18 weeks in metabolic cages. At 40-56 weeks old, rats (n = 9-10/strain) underwent instrumented cystometry under urethane anesthesia. Following cystometry, bladder and urethral tissues (n = 8-9/strain) were harvested for in vitro assessments of contractility in response to carbachol, electric field stimulation, atropine, alpha, beta-methylene ATP, and caffeine. RESULTS: OP rats exhibited increased urinary frequency (p = 0.0031), decreased voided volume (p = 0.0093), and urine flow rate (p = 0.0064) compared to OR rats during uroflowmetry. Bethanechol (10 mg/kg) did not alter uroflowmetry parameters. During cystometry, OP rats exhibited decreased bladder emptying efficiency (p < 0.0001), decreased pressure to generate a void (p < 0.0001), and increased EUS activity during filling (p = 0.0011). Bladder contractility was decreased in OP rats when exposed to carbachol (p < 0.0003) and ATP (p = 0.0004), whereas middle urethral contractility was increased when exposed to carbachol (p = 0.0014), EFS (p = 0.0289), and caffeine (p = 0.0031). CONCLUSION: Impaired cholinergic and purinergic signaling in the bladder may contribute to poor voiding function in OP rats. In addition, increased urethral activity may engage a guarding reflex to augment continence and exacerbate incomplete emptying.


Subject(s)
Urinary Bladder Diseases , Urinary Bladder, Underactive , Animals , Female , Muscles , Rats , Urodynamics
2.
IEEE Trans Vis Comput Graph ; 27(12): 4387-4400, 2021 12.
Article in English | MEDLINE | ID: mdl-32746263

ABSTRACT

In this article, we investigate the effects of active transient vibration and visuo-haptic illusion to augment the perceived softness of haptic proxy objects. We introduce a system combining active transient vibration at the fingertip with visuo-haptic illusions. In our hand-held device, a voice coil actuator transmits active transient vibrations to the index fingertip, while a force sensor measures the force applied on passive proxy objects to create visuo-haptic illusions in virtual reality. We conducted three user studies to understand both the vibrotactile effect and its combined effect with visuo-haptic illusions. A preliminary study confirmed that active transient vibrations can intuitively alter the perceived softness of a proxy object. Our first study demonstrated that those same active transient vibrations can generate different perceptions of softness depending on the material of the proxy object used. In our second study, we evaluated the combination of active transient vibration and visuo-haptic illusion, and found that both significantly influence perceived softness, with with the visuo-haptic effect being dominant. Our third study further investigated the vibrotactile effect while controlling for the visuo-haptic illusion. The combination of these two methods allows users to effectively perceive various levels of softness when interacting with haptic proxy objects.


Subject(s)
Illusions , Virtual Reality , Computer Graphics , Haptic Technology , Humans , Vibration
3.
IEEE Trans Haptics ; 12(4): 470-482, 2019.
Article in English | MEDLINE | ID: mdl-31545743

ABSTRACT

Tactile displays are haptic devices capable of rendering shape and texture information. Unsolved challenges in building tactile shape displays include their traditionally large form factors, low spatial resolution, and high costs. Using electrostatic adhesion to individually brake each pin and a single platform for global actuation, we developed a prototype static refreshable tactile shape display with high spatial resolution (1.7 mm pitch, 0.8 mm pin width; 4 mm pitch, 1.6 mm pin width), high resistance force (76.3 gf static-loading force per pin for 1.6 mm width) and low cost ($0.11 USD per pin for raw material). We present an analytical model of our electroadhesive brake mechanism and evaluate its maximum contact force and robustness in various conditions. To demonstrate the mechanism's potential, we built a static tactile shape display prototype with a 4×2 array of pins controlled using electroadhesive brakes. To further increase maximsum contact force allowed by our device, we develop and evaluate a global mechanical clutch which can be engaged during user interaction. A user study is carried out to compare our static tactile shape display's performance with printed 2.5D tactile graphics in a shape recognition task, and comparable shape recognition rates and response times are observed.


Subject(s)
Equipment Design , Touch , Adhesives , Humans , Models, Theoretical , Static Electricity
4.
Urology ; 133: 72-77, 2019 Nov.
Article in English | MEDLINE | ID: mdl-31465791

ABSTRACT

OBJECTIVE: To assess whether intraurethral anesthesia decreased voiding efficiency (VE), reduced catheterization pain, and impacted urodynamic parameters in healthy adult females. METHODS: In a randomized, double-blind, placebo-controlled trial, participants received two 5 mL doses of either intraurethral aqueous gel or 4% lidocaine gel. The primary outcome was VE during randomized condition uroflow, defined as voided volume/(voided volume + residual volume). The secondary outcomes were pain during catheterization and to confirm previously reported pressure-flow changes. A sample size of 10 per group was planned to detect a clinically significant decrease in VE with a power (1-ß) of 0.99. RESULTS: From October to December 2018, 23 women were screened and 18 were randomized to receive placebo (n = 10) or lidocaine (n = 8). Baseline uroflow VE was similar between the placebo and lidocaine groups (88 ± 6.6% vs 91 ± 5.8%, P = .33). After study drug administration, the changes in VE (post-pre) were similar between placebo and lidocaine groups (-5.4 ± 14% vs 1.7 ± 6.4%, P = .21). Visual analog scores were similar following catheterizations (26.7 ± 12.8 mm vs 36.9 ± 26.8 mm, P = .34). The lidocaine group exhibited lower average flow rates per voided volume (0.04 ± 0.02 s-1 vs 0.02 ± 0.01 s-1, P = .04). CONCLUSION: Intraurethral administration of 4% lidocaine did not decrease VE compared to placebo and did not change pain scores following catheterization. In the lidocaine group, the average flow rate per voided volume was lower. The decrease in flow rate after local anesthesia to the urethra may indicate that urethral sensory feedback contributes to voiding in human micturition.


Subject(s)
Anesthetics, Local/administration & dosage , Lidocaine/administration & dosage , Pain/prevention & control , Urinary Catheterization , Urination/drug effects , Urodynamics/drug effects , Administration, Topical , Adult , Anesthetics, Local/pharmacology , Double-Blind Method , Female , Humans , Lidocaine/pharmacology , Urethra , Urinary Catheterization/adverse effects
5.
Female Pelvic Med Reconstr Surg ; 25(4): 265-270, 2019.
Article in English | MEDLINE | ID: mdl-29300256

ABSTRACT

OBJECTIVES: The aim of the study was to determine whether intraurethral anesthesia decreases voiding efficiency (VE; voided volume/(voided volume + residual volume)) and impacts other urodynamic parameters in healthy female volunteers during urodynamic studies. METHODS: This was a randomized double-blind placebo-controlled study of asymptomatic women aged 18 to 60 years. Subjects completed a visual analog scale and baseline questionnaires to assess pain and lower urinary tract symptoms, respectively. They performed an uninstrumented baseline uroflow, followed by physiologic filling to 250 mL or greater. Subjects were randomized to receive 5 mL of intraurethral aqueous gel or 2% lidocaine gel and then underwent a second uninstrumented uroflow. They then completed complex cystometry, urethral pressure profilometry, and pressure-flow studies. RESULTS: Twenty-three randomized subjects (12 placebo, 11 lidocaine) were included. Baseline uroflow VE was similar between the placebo and lidocaine groups. After study drug administration, VE was not different between groups (89.3 [85.9-93.9] vs 89.5 [82.5-91.7], P = 0.74). There were also no differences between groups in visual analog scale scores, sensation during cystometry, maximum urethral closure pressure, or micturition parameters (maximum detrusor pressure and detrusor pressure at maximum flow). The placebo group had a lower percentage of interrupted flow pattern (0% vs 36%, P = 0.02) and a lower rate of increased electromyographic activity during micturition (25% vs 73%, P = 0.02). CONCLUSIONS: In this pilot study of 23 asymptomatic women, intraurethral administration of lidocaine did not decrease VE compared with placebo. The lidocaine group had a greater percentage of interrupted flow patterns and increased electromyographic activity during micturition.


Subject(s)
Anesthetics, Local/pharmacology , Lidocaine/pharmacology , Urination/drug effects , Urodynamics/drug effects , Adult , Anesthetics, Local/administration & dosage , Double-Blind Method , Electromyography , Female , Gels , Humans , Lidocaine/administration & dosage , Pain, Procedural/prevention & control , Pilot Projects , Urethra/drug effects , Urinary Bladder/drug effects , Urinary Bladder/physiology , Urinary Catheterization , Urine , Young Adult
6.
Neurourol Urodyn ; 38(1): 135-143, 2019 01.
Article in English | MEDLINE | ID: mdl-30350879

ABSTRACT

AIMS: Interstitial cystitis and bladder pain syndrome is a prevalent health concern with inadequate treatments. Neuromodulation has emerged as a therapeutic option to treat patients refractory to standard care. The objective of this study was to determine the efficacy and mechanism(s) of sensory pudendal nerve stimulation on bladder function in cystitis rats. METHODS: Female rats were administered saline (n = 8) or cyclophosphamide (CYP, 150 mg/kg IP, n = 16) and single-trial cystometry experiments were conducted under urethane anesthesia 48 h after injection. Electrical stimulation (0.02-0.22 mA, 10-20 Hz) was delivered to the sensory branch of the pudendal nerve and its effect on the bladder and external urethral sphincter were measured. Stimulation trials were also conducted following bilateral hypogastric nerve transection (HGNT) or pharmacological inhibition of beta-adrenergic receptors (propranolol, 1 mg/kg IV) to determine the mechanisms of bladder inhibition. RESULTS: CYP-induced cystitis decreased bladder capacity (P = 0.0352) and bladder compliance (P = 0.024) by up to 38% of control. Electrical stimulation of the sensory pudendal nerve increased bladder capacity (P < 0.0001) in control and CYP rats by up to 51-52% of their respective baselines. HGNT did not influence bladder inhibition generated by sensory pudendal nerve stimulation in control rats, whereas HGNT and propranolol decreased the efficacy of electrical stimulation in CYP rats. CONCLUSIONS: Sympathetic reflex activity mediates sensory pudendal nerve stimulation in CYP treated but not control rats. These studies demonstrate an alternative approach to neuromodulation in cystitis and establish mechanistic changes during stimulation that may enable the development of novel therapeutics.


Subject(s)
Cystitis/physiopathology , Cystitis/therapy , Pudendal Nerve/physiology , Sympathetic Nervous System/physiopathology , Urinary Bladder/physiopathology , Animals , Antineoplastic Agents, Alkylating , Cyclophosphamide , Cystitis/chemically induced , Electric Stimulation , Female , Rats , Rats, Wistar , Sensation , Urethra/physiopathology , Urodynamics
7.
IEEE Trans Neural Syst Rehabil Eng ; 26(4): 904-910, 2018 04.
Article in English | MEDLINE | ID: mdl-29641395

ABSTRACT

Functional electrical stimulation (FES) can help individuals with physical disabilities by assisting limb movement; however, the change in muscle geometry associated with limb movement may affect the response to stimulation. The aim of this paper was to quantify the effects of elbow flexion and stimulation site on muscle torque production. Contraction torque about the elbow was measured in 12 healthy individuals using a custom elbow flexion testbed and a transcutaneous electrode array. Stimulation was delivered to six distinct sites along the biceps brachii over 11 elbow flexion angles. Flexion angle was found to significantly influence the optimal (i.e., torque-maximizing) stimulation site ( ), with post hoc analysis indicating a proximal shift in optimal stimulation site with increased flexion. Similarly, the biceps stimulation site was found to significantly influence the flexion angle at which peak torque occurred ( ), with post hoc analysis indicating an increase in peak-torque flexion angle as stimulation site is moved proximally up the biceps. Since maximizing muscle force per unit stimulation is a common goal in rehabilitative FES, future efforts could examine methods which compensate for the shift in optimal stimulation site during FES-induced limb movement.


Subject(s)
Elbow/physiology , Electric Stimulation , Muscle, Skeletal/physiology , Adult , Arm , Biomechanical Phenomena , Electrodes , Electromyography , Female , Healthy Volunteers , Humans , Male , Muscle Contraction , Torque , Young Adult
8.
Am J Physiol Renal Physiol ; 313(3): F815-F825, 2017 09 01.
Article in English | MEDLINE | ID: mdl-28637788

ABSTRACT

Obesity is a global epidemic associated with an increased risk for lower urinary tract dysfunction. Inefficient voiding and urinary retention may arise in late-stage obesity when the expulsive force of the detrusor smooth muscle cannot overcome outlet resistance. Detrusor underactivity (DUA) and impaired contractility may contribute to the pathogenesis of nonobstructive urinary retention. We used cystometry and electrical stimulation of peripheral nerves (pudendal and pelvic nerves) to characterize and improve bladder function in urethane-anesthetized obese-prone (OP) and obese-resistant (OR) rats following diet-induced obesity (DIO). OP rats exhibited urinary retention and impaired detrusor contractility following DIO, reflected as increased volume threshold, decreased peak micturition pressure, and decreased voiding efficiency (VE) compared with OR rats. Electrical stimulation of the sensory branch of the pudendal nerve did not increase VE, whereas patterned bursting stimulation of the motor branch of the pudendal nerve increased VE twofold in OP rats. OP rats required increased amplitude of electrical stimulation of the pelvic nerve to elicit bladder contractions, and maximum evoked bladder contraction amplitudes were decreased relative to OR rats. Collectively, these studies characterize a novel animal model of DUA that can be used to determine pathophysiology and suggest that neuromodulation is a potential management option for DUA.


Subject(s)
Electric Stimulation Therapy/methods , Hypogastric Plexus/physiopathology , Muscle, Smooth/innervation , Obesity/complications , Pudendal Nerve/physiopathology , Urinary Bladder/innervation , Urinary Retention/therapy , Urination , Animals , Diet, High-Fat , Disease Models, Animal , Female , Muscle Contraction , Urinary Retention/etiology , Urinary Retention/physiopathology , Urodynamics
9.
IEEE Trans Neural Syst Rehabil Eng ; 25(9): 1397-1408, 2017 09.
Article in English | MEDLINE | ID: mdl-27845664

ABSTRACT

Neuromuscular electrical stimulation (NMES) and Functional Electrical Stimulation (FES) are commonly prescribed rehabilitative therapies. Closed-loop NMES holds the promise to yield more accurate limb control, which could enable new rehabilitative procedures. However, NMES/FES can rapidly fatigue muscle, which limits potential treatments and presents several control challenges. Specifically, the stimulation intensity-force relation changes as the muscle fatigues. Additionally, the delayed response between the application of stimulation and muscle force production, termed electromechanical delay (EMD), may increase with fatigue. This paper quantifies these effects. Specifically, open-loop fatiguing protocols were applied to the quadriceps femoris muscle group of able-bodied individuals under isometric conditions, and the resulting torque was recorded. Short pulse trains were used to measure EMD with a thresholding method while long duration pulse trains were used to induce fatigue, measure EMD with a cross-correlation method, and construct recruitment curves. EMD was found to increase significantly with fatigue, and the control effectiveness (i.e., the linear slope of the recruitment curve) decreased with fatigue. Outcomes of these experiments indicate an opportunity for improved closed-loop NMES/FES control development by considering EMD to be time-varying and by considering the muscle recruitment curve to be a nonlinear, time-varying function of the stimulation input.


Subject(s)
Electric Stimulation/methods , Excitation Contraction Coupling/physiology , Isometric Contraction/physiology , Models, Biological , Muscle Fatigue/physiology , Muscle, Skeletal/physiology , Recruitment, Neurophysiological/physiology , Adult , Computer Simulation , Humans , Male , Muscle Strength/physiology , Nonlinear Dynamics , Time Factors
10.
J Physiol ; 594(13): 3575-88, 2016 07 01.
Article in English | MEDLINE | ID: mdl-27006168

ABSTRACT

KEY POINTS: The sensory components of the urinary bladder are responsible for the transduction of bladder filling and are often impaired with neurological injury or disease. Elevated extracellular ATP contributes, in part, to bladder afferent nerve hyperexcitability during urinary bladder inflammation or irritation. Transforming growth factor-ß1 (TGF-ß1) may stimulate ATP release from the urothelium through vesicular exocytosis mechanisms with minimal contribution from pannexin-1 channels to increase bladder afferent nerve discharge. Bladder afferent nerve hyperexcitability and urothelial ATP release with CYP-induced cystitis is decreased with TGF-ß inhibition. These results establish a causal link between an inflammatory mediator, TGF-ß, and intrinsic signalling mechanisms of the urothelium that may contribute to the altered sensory processing of bladder filling. ABSTRACT: The afferent limb of the micturition reflex is often compromised following bladder injury, disease and inflammatory conditions. We have previously demonstrated that transforming growth factor-ß (TGF-ß) signalling contributes to increased voiding frequency and decreased bladder capacity with cystitis. Despite the functional presence of TGF-ß in bladder inflammation, the precise mechanisms of TGF-ß mediating bladder dysfunction are not yet known. Thus, the present studies investigated the sensory components of the urinary bladder that may underlie the pathophysiology of aberrant TGF-ß activation. We utilized bladder-pelvic nerve preparations to characterize bladder afferent nerve discharge and the mechanisms of urothelial ATP release with distention. Our findings indicate that bladder afferent nerve discharge is sensitive to elevated extracellular ATP during pathological conditions of urinary bladder inflammation or irritation. We determined that TGF-ß1 may increase bladder afferent nerve excitability by stimulating ATP release from the urothelium via vesicular exocytosis mechanisms with minimal contribution from pannexin-1 channels. Furthermore, blocking aberrant TGF-ß signalling in cyclophosphamide-induced cystitis with TßR-1 inhibition decreased afferent nerve hyperexcitability with a concomitant decrease in urothelial ATP release. Taken together, these results establish a role for purinergic signalling mechanisms in TGF-ß-mediated bladder afferent nerve activation that may ultimately facilitate increased voiding frequency. The synergy between intrinsic urinary bladder signalling mechanisms and an inflammatory mediator provides novel insight into bladder dysfunction and supports new avenues for therapeutic intervention.


Subject(s)
Adenosine Triphosphate/physiology , Cystitis/physiopathology , Receptors, Purinergic/physiology , Transforming Growth Factor beta/physiology , Urinary Bladder/innervation , Urinary Bladder/physiology , Animals , Connexins/physiology , Cyclophosphamide , Cystitis/chemically induced , Male , Mice, Inbred C57BL , Nerve Tissue Proteins/physiology , Protein Serine-Threonine Kinases/physiology , Purinergic Antagonists/pharmacology , Pyridoxal Phosphate/analogs & derivatives , Pyridoxal Phosphate/pharmacology , Receptor, Transforming Growth Factor-beta Type I , Receptors, Transforming Growth Factor beta/physiology , Signal Transduction , Urothelium/physiology
11.
Nat Rev Urol ; 13(4): 193-204, 2016 Apr.
Article in English | MEDLINE | ID: mdl-26926246

ABSTRACT

The storage and periodic elimination of urine, termed micturition, requires a complex neural control system to coordinate the activities of the urinary bladder, urethra, and urethral sphincters. At the level of the lumbosacral spinal cord, lower urinary tract reflex mechanisms are modulated by supraspinal controls with mechanosensory input from the urothelium, resulting in regulation of bladder contractile activity. The specific identity of the mechanical sensor is not yet known, but considerable interest exists in the contribution of transient receptor potential (TRP) channels to the mechanosensory functions of the urothelium. The sensory, transduction, and signalling properties of the urothelium can influence adjacent urinary bladder tissues including the suburothelial nerve plexus, interstitial cells of Cajal, and detrusor smooth muscle cells. Diverse stimuli, including those that activate TRP channels expressed by the urothelium, can influence urothelial release of chemical mediators (such as ATP). Changes to the urothelium are associated with a number of bladder pathologies that underlie urinary bladder dysfunction. Urothelial receptor and/or ion channel expression and the release of signalling molecules (such as ATP and nitric oxide) can be altered with bladder disease, neural injury, target organ inflammation, or psychogenic stress. Urothelial receptors and channels represent novel targets for potential therapies that are intended to modulate micturition function or bladder sensation.


Subject(s)
Signal Transduction/physiology , Transient Receptor Potential Channels/metabolism , Urinary Bladder/metabolism , Urothelium/metabolism , Animals , Humans , Muscle, Smooth/innervation , Muscle, Smooth/metabolism , Muscle, Smooth/pathology , Urinary Bladder/innervation , Urinary Bladder/pathology , Urinary Bladder Diseases/diagnosis , Urinary Bladder Diseases/metabolism , Urination/physiology , Urothelium/innervation , Urothelium/pathology
12.
ScientificWorldJournal ; 2015: 545048, 2015.
Article in English | MEDLINE | ID: mdl-25973443

ABSTRACT

We hypothesized that cyclophosphamide- (CYP-) induced cystitis results in oxidative stress and contributes to urinary bladder dysfunction. We determined (1) the expression of oxidative stress markers 3-nitrotyrosine (3-NT), reactive oxygen species (ROS)/reactive nitrogen species (RNS), inflammatory modulators, neuropeptides calcitonin gene-related peptide (CGRP), substance P (Sub P), and adenosine triphosphate (ATP) that contribute to the inflammatory process in the urinary tract and (2) the functional role of oxidative stress in urinary bladder dysfunction with an antioxidant, Tempol, (1 mM in drinking water) combined with conscious cystometry. In CYP-treated (4 hr or 48 hr; 150 mg/kg, i.p.) rats, ROS/RNS and 3-NT significantly (P ≤ 0.01) increased in urinary bladder. CYP treatment increased ATP, Sub P, and CGRP expression in the urinary bladder and cystometric fluid. In CYP-treated rats, Tempol significantly (P ≤ 0.01) increased bladder capacity and reduced voiding frequency compared to CYP-treated rats without Tempol. Tempol significantly (P ≤ 0.01) reduced ATP expression, 3-NT, and ROS/RNS expression in the urinary tract of CYP-treated rats. These studies demonstrate that reducing oxidative stress in CYP-induced cystitis improves urinary bladder function and reduces markers of oxidative stress and inflammation.


Subject(s)
Cyclic N-Oxides/pharmacology , Cyclophosphamide/pharmacology , Oxidative Stress/drug effects , Reflex/drug effects , Urination/drug effects , Urination/physiology , Adenosine Triphosphate/metabolism , Animals , Antioxidants/pharmacology , Calcitonin Gene-Related Peptide/metabolism , Cystitis/chemically induced , Cystitis/drug therapy , Cystitis/metabolism , Cystitis/physiopathology , Disease Models, Animal , Female , Rats , Reactive Nitrogen Species/metabolism , Spin Labels , Substance P/metabolism , Tyrosine/analogs & derivatives , Tyrosine/metabolism
13.
Am J Physiol Regul Integr Comp Physiol ; 306(12): R869-78, 2014 Jun 15.
Article in English | MEDLINE | ID: mdl-24760999

ABSTRACT

Urinary bladder dysfunction presents a major problem in the clinical management of patients suffering from pathological conditions and neurological injuries or disorders. Currently, the etiology underlying altered visceral sensations from the urinary bladder that accompany the chronic pain syndrome, bladder pain syndrome (BPS)/interstitial cystitis (IC), is not known. Bladder irritation and inflammation are histopathological features that may underlie BPS/IC that can change the properties of lower urinary tract sensory pathways (e.g., peripheral and central sensitization, neurochemical plasticity) and contribute to exaggerated responses of peripheral bladder sensory pathways. Among the potential mediators of peripheral nociceptor sensitization and urinary bladder dysfunction are neuroactive compounds (e.g., purinergic and neuropeptide and receptor pathways), sensory transducers (e.g., transient receptor potential channels) and target-derived growth factors (e.g., nerve growth factor). We review studies related to the organization of the afferent limb of the micturition reflex and discuss neuroplasticity in an animal model of urinary bladder inflammation to increase the understanding of functional bladder disorders and to identify potential novel targets for development of therapeutic interventions. Given the heterogeneity of BPS/IC and the lack of consistent treatment benefits, it is unlikely that a single treatment directed at a single target in micturition reflex pathways will have a mass benefit. Thus, the identification of multiple targets is a prudent approach, and use of cocktail treatments directed at multiple targets should be considered.


Subject(s)
Nerve Growth Factors/physiology , Neuropeptides/physiology , Sensory Receptor Cells/physiology , Urinary Bladder Diseases/physiopathology , Urinary Bladder/physiology , Adenosine Triphosphate/physiology , Animals , Disease Models, Animal , Humans , Mice , Neuronal Plasticity/physiology , Urinary Bladder/innervation , Urination/physiology
14.
Biomed Res Int ; 2014: 120525, 2014.
Article in English | MEDLINE | ID: mdl-24738044

ABSTRACT

Bladder pain syndrome (BPS)/interstitial cystitis (IC) is a chronic pain syndrome characterized by pain, pressure, or discomfort perceived to be bladder related and with at least one urinary symptom. It was recently concluded that 3.3-7.9 million women (>18 years old) in the United States exhibit BPS/IC symptoms. The impact of BPS/IC on quality of life is enormous and the economic burden is significant. Although the etiology and pathogenesis of BPS/IC are unknown, numerous theories including infection, inflammation, autoimmune disorder, toxic urinary agents, urothelial dysfunction, and neurogenic causes have been proposed. Altered visceral sensations from the urinary bladder (i.e., pain at low or moderate bladder filling) that accompany BPS/IC may be mediated by many factors including changes in the properties of peripheral bladder afferent pathways such that bladder afferent neurons respond in an exaggerated manner to normally innocuous stimuli (allodynia). The goals for this review are to describe chemokine/receptor (CXCL12/CXCR4; CCL2/CCR2) signaling and cytokine/receptor (transforming growth factor (TGF-ß)/TGF-ß type 1 receptor) signaling that may be valuable LUT targets for pharmacologic therapy to improve urinary bladder function and reduce somatic sensitivity associated with urinary bladder inflammation.


Subject(s)
Chemokines/metabolism , Cytokines/metabolism , Inflammation/metabolism , Inflammation/pathology , Urinary Bladder/metabolism , Urinary Bladder/pathology , Humans , Receptors, Chemokine/metabolism , Receptors, Cytokine/metabolism , Signal Transduction/physiology
15.
Am J Physiol Renal Physiol ; 305(9): F1265-76, 2013 Nov 01.
Article in English | MEDLINE | ID: mdl-23926183

ABSTRACT

Numerous proinflammatory cytokines have been implicated in the reorganization of lower urinary tract function following cyclophosphamide (CYP)-induced cystitis. The present study investigated the functional profile of three pleiotropic transforming growth factor-ß (TGF-ß) isoforms and receptor (TßR) variants in the normal and inflamed (CYP-induced cystitis) rat urinary bladder. Our findings indicate that TGF-ß (1, 2, and 3) and TßR (1, 2, and 3) transcript and protein expression were regulated to varying degrees in the urothelium or detrusor smooth muscle following intermediate (48 h; 150 mg/kg ip) or chronic (75 mg/kg ip; once every 3 days for 10 days), but not acute (4 h; 150 mg/kg ip), CYP-induced cystitis. Conscious, open-outlet cystometry was performed to determine whether aberrant TGF-ß signaling contributes to urinary bladder dysfunction following intermediate (48 h) CYP-induced cystitis. TßR-1 inhibition with SB505124 (5 µM) significantly (p ≤ 0.001) decreased voiding frequency and increased bladder capacity (2.5-fold), void volume (2.6-fold), and intercontraction intervals (2.5-fold) in CYP-treated (48 h) rats. Taken together, these results provide evidence for 1) the involvement of TGF-ß in lower urinary tract neuroplasticity following urinary bladder inflammation, 2) a functional role of TGF-ß signaling in the afferent limb of the micturition reflex, and 3) urinary bladder TßR-1 as a viable target to reduce voiding frequency with cystitis.


Subject(s)
Cystitis, Interstitial/metabolism , Receptors, Transforming Growth Factor beta/genetics , Transforming Growth Factor beta/genetics , Urinary Bladder/metabolism , Urothelium/metabolism , Animals , Cyclophosphamide/administration & dosage , Cystitis, Interstitial/chemically induced , Disease Models, Animal , Female , Muscle, Smooth/metabolism , Protein Isoforms/genetics , Protein Isoforms/physiology , Rats , Rats, Wistar , Receptors, Transforming Growth Factor beta/physiology , Transforming Growth Factor beta/physiology
SELECTION OF CITATIONS
SEARCH DETAIL
...